Related by context. All words. (Click for frequent words.) 70 IMPACT DCM trial 68 BRIM2 68 dose escalation phase 68 phase IIb clinical 67 MIST II 67 phase IIa clinical 66 BRIM3 66 Androxal TM 65 lomitapide 65 Phase IIb kidney transplant 65 Phase Ib IIa 65 Amoxicillin PULSYS Phase III 65 randomized controlled multicenter 65 DSMB recommended 65 Phase Ib II 65 Motesanib 65 Phase Ib clinical 65 trastuzumab DM1 T DM1 64 Fibrillex TM 64 CHAMPION PCI 64 IMPACT DCM 64 Phase 2b kidney transplant 64 Acute Decompensated Heart Failure 64 Phase IIIb clinical 63 confirmatory clinical 63 riociguat 63 EchoCRT 63 acyclovir Lauriad R 63 Proellex TM 63 Phase IIb III 63 randomized Phase IIb 63 alvespimycin 63 APEX PD 63 Phase #b/#a clinical 63 BETAS 63 RSD# oral 63 Dacogen injection 63 PEARL SC 63 recurrent malignant glioma 63 treatment naive genotype 63 subcutaneous PRO 62 PFO migraine 62 rALLy clinical trial 62 Phase IIB 62 phase III ACCLAIM 62 STRIDE PD 62 rALLy 62 phase IIa 62 thorough QT 62 multicentre randomized controlled 62 Phase #/#a 62 HCV RESPOND 2 62 Phase III VISTA 62 recurrent glioblastoma multiforme 62 CALGB # [002] 62 tramiprosate Alzhemed TM 62 phase IIIb 62 ADVANCE PD 62 dose escalation clinical 62 UVIDEM 62 ELACYT 62 forodesine 62 PROMACTA 62 BrachySil TM 61 ABSORB clinical 61 AGILECT R 61 TBC# 61 Cloretazine 61 multicenter randomized controlled 61 multicenter Phase II 61 huN# DM1 61 CUSTOM III 61 PRIMO CABG 61 Cloretazine R VNP#M 61 LEUKINE 61 multicenter clinical 61 metastatic HRPC 61 MEND CABG 61 CIMZIA TM certolizumab pegol 61 Dose escalation 61 AVN# Phase 61 StemEx 61 catheter occlusion 61 Phase 1a clinical 61 dexanabinol 61 develop HBV reactivation 61 Phase IIIb study 61 multicenter Phase 61 cangrelor 61 ENESTnd 61 PrevOnco ™ 61 placebo controlled clinical 61 Phase 2b study 61 Phase III Pivotal 61 biliary tract cancer 61 SYMMETRY trial 61 incyclinide 61 PRIMO CABG2 61 GENASIS clinical 60 Microplasmin 60 Specifid 60 EMPHASIS HF trial 60 ENDEAVOR III 60 Genasense ® 60 ReN# 60 Phase IIb clinical 60 PROMACTA CARES 60 SinuNase TM 60 CLARITY study 60 assessing T DM1 60 YONDELIS 60 PROTECT AF 60 CONQUER OB 60 Hepatocellular Carcinoma HCC 60 DAPT 60 ENDEAVOR IV 60 ABSORB trial 60 XL# SAR# 60 blinded randomized placebo controlled 60 squalamine 60 VICTOR E1 60 GAMMAGARD 60 Phase Ib study 60 Phase 2a clinical 60 Phase 1b clinical 60 registrational Phase 60 ongoing Phase 1b 60 BST CarGel R 60 oral methylnaltrexone 60 Bezielle 60 treatment naïve genotype 60 Cloretazine ® 60 Urocortin 2 60 Fx #A 60 EVIZON TM 60 Traficet EN 60 Phase IIb clinical trials 60 SEPET TM 60 TransVax 60 randomized #:#:# 60 relapsed MM 60 EOquin TM 60 Multicenter Automatic Defibrillator Implantation 60 Phase IIb REGENESIS 60 Luveniq 60 PSMA ADC 60 tolevamer 60 trial evaluating Prochymal 59 metastatic GIST 59 MYTHOS trial 59 recurrent glioma 59 Medidur FA 59 retinal vein occlusion induced 59 ADMIRE HF 59 Hedgehog Pathway Inhibitor 59 Alfimeprase 59 confirmatory Phase III 59 COSIRA trial 59 phase IIb trial 59 CEQ# 59 Dextofisopam 59 carotid endarterectomy CEA 59 Augment Injectable 59 keloid scarring 59 double blinded placebo 59 multicenter randomized placebo controlled 59 phase Ib clinical 59 Phase III confirmatory 59 alfimeprase 59 Ataluren 59 PI3K/Akt pathway inhibitor 59 tremelimumab 59 oral rivaroxaban 59 Phase III Psoriasis 59 Phase III randomized controlled 59 Plicera 59 modified REGENESIS Phase IIb 59 Anturol TM 59 designated HVTN 59 Mipomersen 59 TASKi3 59 SomatoKine R 59 Phase 2b clinical 59 ancrod 59 LibiGel Phase III 59 Bayer HealthCare Onyx Pharmaceuticals 59 AA Amyloidosis 59 MAGE A3 ASCI 59 Vascular Wrap 59 BR.# 59 Certolizumab 59 brivaracetam 59 senicapoc 59 CHARM Added 59 lumiliximab 59 Phase IIIb 59 SNT MC# 59 AIM HIGH 59 Pivotal Phase III 59 Refractory Angina 59 metastatic CRC 59 oral ridaforolimus 59 ABSSSI 59 opioid induced bowel dysfunction 59 rindopepimut 59 PRECiSE 59 CARE HF 59 Randomized controlled 59 DEB# 59 placebo controlled Phase III 59 phase IIb 59 OAB overactive bladder 59 MAXY alpha 59 Cloretazine VNP#M 59 GENASIS trial 59 Vascugel 59 HCD# [002] 59 Cimzia TM 59 OPT CHF 59 COU AA 59 Certolizumab pegol 59 INCB# [001] 59 MIVI III 59 CURE AF 59 Forodesine HCl 59 Aurexis 59 Trovax 59 mg/m2 cohort 59 PANVAC VF 58 Kamada AAT 58 Curaxin CBLC# 58 intravenous methylnaltrexone 58 phase Ib 58 NeuroFlo 58 Lung Rx 58 GATTEX ® 58 Phase IIa trials 58 ATACAND 58 phase III SIMPADICO 58 AERx ® 58 delivers fluocinolone acetonide FA 58 LUX Lung 58 Stimuvax R 58 HCV SPRINT 58 via intradermal injections 58 EXJADE 58 ZACTIMA 58 GSK# [001] 58 EXPLORE Xa 58 advanced metastatic prostate 58 including eniluracil ADH 58 REVIVE Diabetes 58 Phase III psoriasis 58 relapsing remitting MS RRMS 58 Glypromate 58 GOUT 58 PhG alpha 1 58 Dacogen decitabine 58 Troxatyl 58 randomized Phase 2b 58 de novo kidney transplant 58 vernakalant hydrochloride 58 budesonide foam 58 Phase III metastatic melanoma 58 placebo controlled Phase 58 EVEREST II 58 fosbretabulin 58 NP2 Enkephalin 58 prospective multicenter 58 MADIT II 58 GetGoal Phase III 58 relapsed leukemia 58 Proxinium TM 58 ZOLINZA 58 RSD# 58 Vectibix monotherapy 58 NATRECOR R 58 APTIVUS 58 CIMZIA TM 58 Phase 2a clinical trials 58 randomized multicentre 58 interferon beta 1b 58 ToGA 58 Phase 2a trial 58 eosinophilic asthma 58 Virulizin R 58 AQ4N 58 MIRCERA 58 clinical pharmacology studies 58 StemEx R 58 volociximab 58 calcineurin inhibitor 58 Uricase PEG 58 Phase IIa clinical 58 fostamatinib 58 Phase #b/#a 58 urocortin 2 58 Octreolin 58 Targretin capsules 58 UPLYSO 58 prospective multicenter study 58 MEND CABG II 58 evaluating TLN 58 Fibrin Pad 58 ORENCIA ® 58 anecortave acetate 58 DASISION 58 Randomized Phase II 58 metastatic malignant 58 Acute Radiation Syndrome ARS 58 CAMMS# 58 Xanafide 58 LHRH receptor positive 58 IIb clinical trial 58 huC# DM4 58 CCX# B 58 enoximone capsules 58 ELND# 58 dosing cohort 58 Raptiva r 58 subcutaneous ORENCIA 58 vidofludimus 58 talabostat 58 tafamidis 58 sitaxsentan 58 Teriflunomide 58 ENGAGE AF TIMI 58 inhaled AAT 58 hormone LHRH antagonist 58 CLIRS trial 58 motesanib 58 Tectin TM 58 multicenter Phase III 58 recurrent glioblastoma 58 AIR CF2 58 CytoFabTM 58 APEX AMI 58 Phase III HEAT 58 MYDICAR 58 TELCYTA 58 mRCC 58 ORMD 58 BLP# Liposome Vaccine 58 Initiate Phase II 58 IL# PE#QQR 58 evaluating mipomersen 58 aerosolized KL4 surfactant 58 AZOR 58 R#/MEM # 58 imetelstat GRN#L 58 subcutaneous methylnaltrexone 58 Enzastaurin 58 label dose titration 58 VALOR trial 58 oral talactoferrin 58 Phase 2a 58 evaluating Actimmune 58 BLA filing 58 ACTIVE W 58 PDE4 inhibitor 58 AIR CF3 58 elacytarabine 58 randomized controlled Phase 58 TKM Ebola 58 CIMZIA ™ 57 multicentre randomized 57 ara C 57 Prestara 57 Phase Ib 57 SUCCEED trial 57 ataluren 57 non splenectomized 57 CA9 SCAN 57 HQK 57 lipoprotein lipase deficiency LPLD 57 CIMZIA R 57 herpetic keratitis 57 Alzhemed TM 57 TAXUS VI 57 Sibutramine Cardiovascular Outcomes 57 MOZOBIL 57 pivotal bioequivalence 57 Phase Ia 57 AMEVIVE 57 occlusion PAO 57 rhIGF-I/rhIGFBP-3 57 OrCel ® 57 dose titration 57 teduglutide 57 EVIZON TM squalamine lactate 57 lorvotuzumab mertansine 57 undergone splenectomy 57 weekly subcutaneous injections 57 ECASS 57 antibody MAb 57 VP# [004] 57 ExTRACT TIMI 57 novel VDA molecule 57 acetonide FA 57 IIa trial 57 AMPAKINE CX# 57 HuMax EGFr 57 Phase III registrational 57 ALSYMPCA 57 everolimus eluting stents 57 GLASS ART Trial 57 midstage clinical 57 confirmatory Phase IIIb 57 elotuzumab 57 AFRS TM 57 PrevOnco 57 Canvaxin 57 Cand5 57 Dextofisopam Phase 2b 57 acute PAO 57 evaluating CK # 57 Phase IIb trials 57 Genz # 57 Phase III placebo controlled 57 oxypurinol 57 BAY #-# 57 alvimopan 57 TELINTRA 57 PEGINTRON REBETOL combination 57 vaccine Stimuvax 57 MKC# MKC# PP 57 PDX pralatrexate 57 chronic myocardial ischemia 57 VELCADE melphalan 57 GW# [003] 57 eritoran 57 IV NSCLC 57 phase 2a 57 adjuvant colon cancer 57 OvaRex ® MAb 57 pretransplant 57 Sprycel dasatinib 57 TEC #OL 57 verteporfin 57 denufosol 57 relapsed AML 57 dose cohort 57 Excellarate TM 57 PROLACRIA 57 evaluating Prochymal 57 subcutaneous formulation 57 TACI Ig 57 AGGRASTAT ® 57 MKC# MT 57 Xcellerated T Cells 57 LUMINATE 57 Resten NG 57 dose escalation Phase 57 pharmacokinetic PK study 57 Recurrent Glioblastoma 57 carcinoid syndrome 57 relapsed refractory multiple myeloma 57 periodically reassessed 57 BHT DNA 57 #mg ATC 57 Matrix Phase 2b 57 Phase 2b 57 Delcath Phase III 57 ALN VSP Phase 57 talactoferrin 57 OMS# 57 RELOVAIR ™ 57 Hydroxyurea 57 Factor VIIa 57 smoldering multiple myeloma 57 paclitaxel poliglumex 57 Pivotal Trial 57 eSVS MESH 57 PRECISE Trial 57 NEUVENGE 57 cilengitide 57 HF ACTION 57 Pivotal Clinical Trial 57 neurogenic orthostatic hypotension 57 refractory gout 57 Ocrelizumab 57 Medidur TM FA 57 BCIRG 57 GRNVAC1 57 Central Retinal Vein 57 TRO# 57 CATIE AD 57 AVOREN 57 ONCONASE R 57 galiximab 57 epoetin alpha 57 Dupuytren Disease 57 Shigamabs ® 57 Cinquil 57 refractory CLL 57 GLP toxicology studies 57 SPIRIT FIRST 57 Phase 1a 57 Angiox R 57 PNP inhibitor 57 granted Ortec 57 Prospective Randomized 57 neratinib 57 ASCEND HF 57 ProCord 57 E2F Decoy 57 RhuDex 57 Myoblast 57 corticosteroid dexamethasone 57 Tarceva TM 57 Triapine R 57 ruxolitinib 57 AZILECT R 57 metastatic neuroendocrine tumors 57 RE LY ® 57 anagrelide 57 Levacor 57 MERLIN TIMI 57 unresectable malignant mesothelioma UMM 57 dipyridamole plus 57 Selective Electrochemical Tumor Ablation 56 recurrent NSCLC 56 HuCNS SC cells 56 EDEMA4 56 Ophena 56 Allovectin 7 ® 56 docetaxel Taxotere ® 56 ThermoDox ® clinical 56 CBLC# 56 Virulizin ® 56 multicenter randomized 56 Genasense ® oblimersen 56 structure infections ABSSSI 56 Lenocta 56 cancer neuroendocrine tumor 56 Prostate AdenoCarcinoma Treatment 56 registrational 56 IPLEX 56 methylnaltrexone 56 Severe Sepsis 56 Dyloject TM 56 SomatoKine 56 visilizumab 56 interferon ribavirin 56 acute peripheral arterial 56 azilsartan medoxomil 56 injectable enzyme 56 prospective randomized placebo 56 Phase 1b clinical trials 56 OZURDEX ® 56 NO# [002] 56 unique alkylating agent 56 European Sepsis Trial 56 warfarin therapy 56 Aflibercept 56 Zemplar Capsules 56 VNP#M 56 bardoxolone 56 Ceflatonin R 56 APEX AMI trial 56 esophageal candidiasis 56 blinded randomized 56 HGS ETR1 mapatumumab 56 Prosaptide 56 QLT# 56 Gentamicin Surgical Implant 56 Exherin TM 56 taxane resistant 56 Initiate Phase 56 dirucotide 56 lenalidomide Revlimid R 56 EndoTAG TM -1 56 Phase 1b 56 intravitreal insert 56 aflibercept VEGF Trap 56 GEM OS1 56 PERSEUS 56 interferon beta therapy 56 lintuzumab SGN 56 multicenter randomized Phase 56 GATTEX ™ 56 BrachySil ™ 56 interferon gamma 1b 56 PRT# 56 mertansine 56 Panzem R 56 reslizumab 56 oral prodrug 56 Aptivus ® 56 OMP #R# 56 phase IIb study 56 Phase IIB clinical 56 PREGNANT PROCHIEVE Extending GestatioN 56 Investigational Device Exemption IDE 56 neurologic progression 56 NSABP B 56 VEGFR2 inhibitor 56 PF # [002] 56 PROSTVAC ® 56 severe hypercholesterolemia 56 acute HAE attacks 56 glufosfamide 56 malignant ascites 56 EVIZON 56 Phase lll 56 refractory NSCLC 56 Neuvenge 56 E1 INT TM 56 icatibant 56 chronic thromboembolic pulmonary 56 kidney urologic 56 IRX 2 56 ASSERT trial 56 Oxypurinol 56 active comparator 56 ACCORD Lipid 56 rALLy trial 56 patients undergoing CABG 56 ruboxistaurin 56 tramiprosate ALZHEMED TM 56 fallopian tube cancers 56 ENMD # 56 Stedivaze 56 Tanespimycin 56 deforolimus 56 recurrent metastatic ovarian cancer 56 Cangrelor 56 Sym# 56 neurocognitive outcomes 56 National Emphysema Treatment 56 percutaneous cryoablation 56 confirmatory Phase 3 56 PRECISE trial 56 randomized discontinuation 56 intravesical infusion therapy 56 oral picoplatin 56 Atrasentan 56 Elocalcitol 56 XYOTAX TM 56 oxymorphone ER 56 Inhaled nitric oxide 56 VITAL Trial 56 Dalbavancin 56 ORBIT II 56 JAK#/JAK# inhibitor CYT# 56 REGENESIS Phase IIb 56 liver resection 56 Nuvion 56 velafermin 56 albiglutide 56 prospective randomized multicenter 56 POSIDUR TM 56 multicenter placebo controlled 56 elective PCI 56 NEUMUNE 56 mg kg dose 56 ENABLE Phase 2 56 Lofexidine 56 crizotinib PF # 56 treat chronic sinusitis 56 Zevalin consolidation 56 #mg QD [002] 56 BEXXAR Therapeutic Regimen 56 LibiGel ® 56 relapsed Hodgkin lymphoma 56 Lixivaptan 56 Phase 2b trial 56 decitabine 56 formal pharmacokinetic PK 56 AKT inhibitor 56 omecamtiv mecarbil 56 Albuferon Phase 56 BYSTOLIC 56 OncoGel 56 muraglitazar 56 axitinib 56 Carotid Revascularization Endarterectomy vs. 56 bowel resection 56 ENRICH trial 56 Cleviprex TM clevidipine 56 ularitide 56 EGFR TKI 56 TLK# 56 Testosterone MDTS ® 56 IIa clinical trials 56 Ceflatonin 56 opioid bowel dysfunction 56 Raptiva ® 56 PREZISTA r 56 GEM OS2 56 thrombolytic agent 56 TRISENOX 56 IMA# 56 SPEAR Study 56 Cloretazine R 56 Tolvaptan 56 ISTODAX 56 LymphoStat B Phase 56 PREVENT IV 56 secondary efficacy endpoint 56 revascularization procedure 56 dosage regimens 56 Neo Bladder Augment 56 EmbraceAC 56 Phase IIb 56 Vernakalant 56 TASKi2 56 Pafuramidine 56 Panzem R NCD 56 Triapine 56 TG MV 56 HuMax CD4 56 either acutely decompensated 56 recurrent metastatic 56 Surgical resection 56 abacavir containing 56 recombinant tissue plasminogen 56 prospective multicenter randomized 56 MGd 56 Glufosfamide 56 AGGRASTAT R 56 pouchitis 56 ACTILON 56 refractory colorectal cancer 56 Phase IIb trial 56 Dapagliflozin 56 CINTREDEKIN BESUDOTOX 56 dosing cohorts 56 Trofex 56 Rheos System 56 OncoVEX GM CSF 56 Prodarsan 56 cetrorelix pamoate 56 somatostatin analog 56 SCENESSE ® 56 MYDICAR ® 55 Vascugel ® 55 subcutaneous SC 55 NABTT 55 REALITY Trial 55 prospective nonrandomized 55 randomized Phase III 55 tumor lysis syndrome 55 resectable pancreatic cancer 55 TNFerade TM 55 HuMax TAC 55 sapacitabine CYC# 55 postoperative chemotherapy 55 figitumumab 55 sargramostim 55 Urocidin 55 PEG SN# 55 multicenter prospective 55 metastatic colorectal carcinoma 55 Alocrest 55 advanced carcinoid 55 GLP1 agonist 55 MGCD# clinical trials 55 pain palliation 55 alkylating agent 55 enzastaurin 55 gefitinib Iressa 55 PLK1 SNALP 55 RhuDex ® 55 docetaxel Taxotere R 55 Committee IDMC 55 multicenter randomized clinical 55 TYZEKA 55 unblinding 55 acyclovir Lauriad ® 55 budesonide MMX Phase III 55 doxorubicin Transdrug ® 55 SparVax TM 55 Xelox 55 ORENCIA R 55 REMINYL ® 55 neurogenic bladder 55 CLARITY TIMI 55 hyperoxaluria 55 AeroLEF TM 55 PROPEL trial 55 Current Controlled Trials 55 cathepsin K inhibitor 55 controlled multicenter 55 recombinant PSMA vaccine 55 preterm newborns 55 Diamyd r vaccine 55 romiplostim 55 CLL SLL 55 ascending dose 55 remission induction 55 Tumor Response 55 catheter occlusion CO 55 ICA # 55 cysteamine bitartrate 55 gamma secretase inhibitor 55 AERAS-#/Crucell Ad# 55 Phase III TRIST 55 eprotirome 55 Hsp# Inhibitor 55 receptor tyrosine kinase inhibitor 55 confirmatory Phase 55 apricitabine ATC 55 Neovasc Reducer 55 relapsed ALL 55 Dural Sealant 55 Heterozygous Familial Hypercholesterolemia 55 ACTEMRA TM 55 metastatic bladder 55 AVADO 55 IMC #B 55 randomized crossover 55 randomized blinded 55 histologically confirmed 55 PAOD 55 lung resection 55 SinuNase 55 LCP Tacro 55 LymphoStat B TM 55 Zerenex 55 evaluating REVLIMID 55 PDE# inhibitors 55 ThermoDox R 55 CMV vaccine 55 TTF Therapy 55 serum phosphorous 55 Thrombolysis 55 dalbavancin 55 velaglucerase alfa 55 Resolute DES 55 titration phase 55 Alvesco R 55 rFVIIa 55 PSVT 55 lapatinib Tykerb 55 Aurora kinase inhibitor 55 Diabetic Macular Edema 55 ENDEAVOR II 55 APPRAISE 55 synthetic retinoid 55 relapsing multiple sclerosis 55 canakinumab 55 nonrandomized 55 Phase III clinical 55 eculizumab therapy 55 Genasense oblimersen sodium Injection 55 Gliadel Wafer 55 RezularTM 55 Phase III Clinical Trial 55 Phase 2b randomized 55 tesmilifene 55 BioNumerik 55 Vicinium TM 55 midstage trials 55 psoriatic arthritis PsA 55 SIR Spheres 55 OHR/AVR# 55 refractory metastatic colorectal cancer 55 Zenvia ™ 55 Urocidin TM 55 Aplidin 55 BLOOM Behavioral modification 55 concurrent chemoradiation 55 apricitabine 55 Deferiprone 55 myoblast 55 hyperplasia BPH 55 Hedgehog antagonist 55 eltrombopag 55 vismodegib 55 evaluating picoplatin 55 metastatic CRPC 55 lanreotide 55 JAK inhibitor 55 vaginally administered lidocaine 55 EDEMA3 55 orally administered inhibitor 55 myopic CNV 55 Endarterectomy 55 teriflunomide 55 Gabapentin GR 55 DCVax ® Brain 55 HPTN 55 pancreatectomy 55 GnRH antagonist 55 Cethrin 55 R lenalidomide 55 PREOS R 55 microplasmin 55 refractory chronic lymphocytic 55 bicifadine 55 HYVET 55 bavituximab monotherapy trial 55 AZILECT ® 55 Phase 1b trial 55 VA# [002] 55 ONGLYZA ™ 55 noninfectious uveitis 55 CTAP# Capsules 55 Catena ® 55 trastuzumab Herceptin ® 55 pharmacokinetic PK 55 AERx iDMS 55 CCX# 55 Initiates Phase II 55 GRAVITAS trial 55 OncoVEX 55 dacetuzumab 55 Adlea 55 canagliflozin 55 bile duct tumor 55 Tovaxin TM 55 ATL# [001] 55 GENASIS 55 Oncotype DX colon cancer 55 Phase III pivotal 55 Corlux 55 Rezular 55 Keppra ® injection 55 Tykerb lapatinib 55 orBec 55 clazosentan 55 investigational antiplatelet agent 55 Phase III multicenter 55 Mycograb 55 orally administered synthetic retinoid 55 novel oral anticoagulant 55 LEVADEX TM 55 Vitaxin 55 Omigard 55 Decompensated Heart Failure 55 Rescula 55 omacetaxine mepesuccinate 55 HDL Selective Delipidation 55 prospective multicentre 55 NCT# ClinicalTrials.gov 55 receiving chemoradiation therapy 55 placebo controlled multicenter 55 Endologix Powerlink System 55 genomic biomarker 55 Phase #b/#a trial 55 PRE SURGE 55 octreotide implant 55 CRLX# 55 Systemic Sclerosis 55 IIIA NSCLC 55 papillary renal cell carcinoma 55 TMC# C# 55 CALERIE 55 Omacetaxine 55 PARTNER Trial 55 subanalysis 55 Allovectin 7 55 randomized multicenter trial 55 INSPIRE Trial Phase III 55 ReN# stem cell 55 aflibercept 55 Simulect 55 R# #mg BID 55 DU #b 55 Exelixis XL# 55 Entereg TM 55 fenretinide 55 Empatic ™ 55 Saxagliptin 55 inhibitor RG# 55 phase IIb III 55 leukemia AML 55 EQUIP OB 55 cediranib 55 oral anticoagulant therapy 55 PROCHYMAL 55 DEEP AF 55 GVAX 55 RESTORE CLI trial 55 Proleukin 55 tiapamil 55 beta blocker therapy 55 alefacept 55 Veronate 55 Phase Ib clinical trials 55 systemic anaplastic large 55 nab paclitaxel 55 Degarelix 55 autologous bone marrow 55 certolizumab 55 trastuzumab emtansine T DM1 55 miglustat 55 octreotide acetate 55 bevasiranib 55 COMFORT II 55 sodium thiosulfate STS 55 ONTARGET R 55 severe oral mucositis 55 allogeneic SCT 55 generation purine nucleoside 55 percutaneous aortic valve 55 multicenter dose escalation 55 genotypic resistance